Predictors for the development of neurological immune‐related adverse events of immune checkpoint inhibitors and impact on mortality

Abstract

Neuro-irAEs are not associated with increase in overall mortality. Potential predictors for the development of neuro-irAEs are younger age, melanoma, prior chemotherapy and resection, CTLA-4, or combination ICIs exposure.